Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care

Reuters

2025/07/23

Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care

Koninklijke Philips NV has announced a significant advancement in prostate cancer care with the FDA 510(k) clearance for its latest image-guided navigation technology, Philips UroNav. This approval marks a major step in supporting prostate cancer diagnosis by offering clinicians more precise guidance, thereby enhancing patient care. The upgraded UroNav system integrates pre-procedural MRI with real-time ultrasound imaging, providing a dynamic and comprehensive view of the targeted area for minimally invasive procedures. Additionally, it includes a new advanced annotation workflow aimed at improving the accuracy of focal therapy procedures. This development is part of Philips' broader effort to streamline complex workflows in prostate cancer care, equipping clinicians with the necessary tools to deliver better and more precise treatment options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royal Philips NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001119272-en) on July 23, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2553324356"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553324356\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553324356?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-23 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553324356","market":"nz","top_or_hot":-1,"title":"Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Koninklijke Philips NV has announced a significant advancement in prostate cancer care with the FDA 510(k) clearance for its latest image-guided navigation technology, Philips UroNav. This approval marks a major step in supporting prostate cancer diagnosis by offering clinicians more precise guidance, thereby enhancing patient care. The upgraded UroNav system integrates pre-procedural MRI with real-time ultrasound imaging, providing a dynamic and comprehensive view of the targeted area for minimally invasive procedures. Additionally, it includes a new advanced annotation workflow aimed at improving the accuracy of focal therapy procedures. This development is part of Philips' broader effort to streamline complex workflows in prostate cancer care, equipping clinicians with the necessary tools to deliver better and more precise treatment options.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royal Philips NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001119272-en) on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhilips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-23 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Koninklijke Philips NV has announced a significant advancement in prostate cancer care with the FDA 510(k) clearance for its latest image-guided navigation technology, Philips UroNav. This approval marks a major step in supporting prostate cancer diagnosis by offering clinicians more precise guidance, thereby enhancing patient care. The upgraded UroNav system integrates pre-procedural MRI with real-time ultrasound imaging, providing a dynamic and comprehensive view of the targeted area for minimally invasive procedures. Additionally, it includes a new advanced annotation workflow aimed at improving the accuracy of focal therapy procedures. This development is part of Philips' broader effort to streamline complex workflows in prostate cancer care, equipping clinicians with the necessary tools to deliver better and more precise treatment options.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royal Philips NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001119272-en) on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDL82sn9P:1","article_id":"2553324356","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553324356","pubTimestamp":1753275628,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Koninklijke Philips NV has announced a significant advancement in prostate cancer care with the FDA 510 clearance for its latest image-guided navigation technology, Philips UroNav. This approval marks a major step in supporting prostate cancer diagnosis by offering clinicians more precise guidance, thereby enhancing patient care. The upgraded UroNav system integrates pre-procedural MRI with real-time ultrasound imaging, providing a dynamic and comprehensive view of the targeted area for minimally invasive procedures. Additionally, it includes a new advanced annotation workflow aimed at improving the accuracy of focal therapy procedures. This development is part of Philips' broader effort to streamline complex workflows in prostate cancer care, equipping clinicians with the necessary tools to deliver better and more precise treatment options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"飞利浦获得FDA 510(k)许可，用于前列腺癌护理的先进图像引导导航技术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9},"content_text":"Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care\n    \n\n        Koninklijke Philips NV has announced a significant advancement in prostate cancer care with the FDA 510(k) clearance for its latest image-guided navigation technology, Philips UroNav. This approval marks a major step in supporting prostate cancer diagnosis by offering clinicians more precise guidance, thereby enhancing patient care. The upgraded UroNav system integrates pre-procedural MRI with real-time ultrasound imaging, providing a dynamic and comprehensive view of the targeted area for minimally invasive procedures. Additionally, it includes a new advanced annotation workflow aimed at improving the accuracy of focal therapy procedures. This development is part of Philips' broader effort to streamline complex workflows in prostate cancer care, equipping clinicians with the necessary tools to deliver better and more precise treatment options.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royal Philips NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001119272-en) on July 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}